Mayne Pharma | MYX - 销售成本



金融业
股票价格
AUD
资产
AUD 1.14B
现金及等价物
AUD 110.07M
销售成本
AUD 43.74M
流动资产
AUD 460.59M
流动负债
AUD 313.94M
债务
AUD 38.82M
EBIT
AUD -16.2M
EBITDA
AUD 20.9M
员工
450
EPS每股收益
AUD -0.15
股本和储备
AUD 454.19M
销售毛利
AUD 86.13M
债务利息支出
AUD 1.2M
贷款资金
AUD 2.66M
市值
AUD 209.28M
净收入
AUD -103.68M
营业费用
AUD 103.54M
营业利润
AUD -3.3M
普通股股本
AUD 81.25M
税前利润
AUD -14.7M
销售收入
AUD 212.07M
销售和管理费用
AUD 54.8M
股票
AUD 74.63M
贸易债权人
AUD 30.25M
应收帐款人
AUD 193.22M


销售成本 更改 日
Ansell USD 605.3M 351.2M 2025-12
Avita Medical AUD 3.3M 166K 2025-12
Cochlear AUD 319.2M 160.35M 2025-12
CSL USD 3.87B 2.08B 2025-12
Healius AUD 218.7M 110.8M 2025-06
Integral Diagnostics AUD 11.53M 146K 2024-06
Medical Developments International AUD 7.09M 4.91M 2025-12
Nanosonics AUD 24.22M 1.11M 2025-12
Polynovo AUD 9.02M 3.51M 2025-12
Ramsay Health Care AUD 3.05B 78.7M 2025-12
ResMed USD 536.28M 21.52M 2025-12
Sigma Healthcare AUD 1.55B 165.16M 2024-12
Sonic Healthcare AUD 751.66M 801.13M 2024-12
Telix Pharmaceuticals AUD 221.36M 20.78M 2025-12